HealthMyne is unveiling and providing demonstrations of their new commercial platform at RSNA 2016.
The Quantitative Imaging Decision Support (QIDS)™ software platform combines imaging data with electronic medical record, radiation therapy and other clinical systems information to provide clinical decision support in the primary read.
Currently focused on Radiology and Oncology, with future expansion into other specialties, QIDS (pronounced ‘quids’) is uniquely designed to positively impact clinical productivity and prepares Radiologists for the transition to Value-Based Payment.
HealthMyne asserts that in order for Radiologists to extend their value as a member of the care team, highly curated evidence-based narratives, imaging analytics, and patient cohort analysis must be generated to provide clinical decision support in the primary read thereby enabling improved cancer diagnosis, staging and treatment.
“Our mission at HealthMyne is to support Radiology in its transition from a volume-based provider to a value-based quantitative imaging, analytics and point of care clinical decision support collaborative partner with multiple specialties starting with Oncology”, stated Arvind Subramanian, the CEO of HealthMyne.
“We have developed a platform that allows Radiologists to meet this new paradigm by allowing them to add value to the equation while also increasing productivity.”
HealthMyne, Inc. is focused on delivering Quantitative Imaging Decision Support (QIDS)™ for Radiology and Oncology with expansion to other clinical specialties and non-US markets over time.
The company’s FDA-cleared software platform delivers image quantification, analytics and clinical information (EMR, RT, other data) into the primary workflow to drive clinical productivity; provides curated medical content, analysis and reporting to optimize clinical collaboration and enable precise patient management; and supports data mining for clinical, translational and commercial research.